Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Key Inclusion Criteria * Ovarian cancer that is not refractory or resistant to platinum-based therapy (refactory=progression while receiving any previous platinum regimen; resistant=progression within 6 months of any previous platinum regimen) * Recipients of platinum/taxane-based chemotherapy as frontline regimen for ovarian cancer * An Eastern Cooperative Oncology Group performance status ≤1 * Up to 4 prior lines of therapy for ovarian cancer * Two groups are eligible: Group 1. Women who have not met the criteria for progressive disease following their most recent chemotherapeutic regimen were required to have: * Demonstrated partial response or stable disease following the most recent chemotherapy regimen * Evaluable or measurable disease, detected by baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan * Received the last dose of their most recent chemotherapeutic regimen for ovarian cancer within 4 to 12 weeks of the first administration of ipilimumab Group 2: Women with disease progression while receiving or following the last dose of the most recent chemotherapeutic regimen were required to have: * Measurable disease on a CT or MRI scan performed within 28 days of first dose of ipilimumab. * Received the last dose of their most recent chemotherapeutic regimen for ovarian cancer at least 4 weeks prior to the first administration of ipilimumab. Key Exclusion Criteria * Histologic diagnosis of borderline, low malignant potential epithelial carcinoma * For Group 1, women with complete response on the most recent ovarian carcinomatherapy * Presence of known brain metastases * Second malignancy active within the past 5 years, with the exception of locally curable cancers that have no need for subsequent therapy * Documented history of severe autoimmune or immune-mediated symptomatic disease requiring prolonged systemic immunosuppressive treatment * History of motor neuropathy considered to be of autoimmune origin or the of grade 2 or higher peripheral neuropathy * History of toxic epidermal necrolysis * Prior therapies with immunosuppressive agents within the last 2 years (excluding low-dose corticosteroids) and prior therapies with cytotoxic drugs within 4 weeks * Chronic use of systemic immunosuppressive drugs, ongoing use of immunotherapy or biologic therapy for the treatment of cancer, or prior use of ipilimumab or any immune-stimulating agent.